More Americans with diabetes will get a break on their insulin costs in 2024. Sanofi is joining the nation's two other major insulin manufacturers in offering either price caps or savings programs ...

Ahead of World Diabetes Day, Doctors Without Borders/Médecins Sans Frontières (MSF) called for all insulin manufacturers to provide injection pen devices at $1 per pen. The humanitarian organization ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes lowered their HbA1c from ...

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec) injection, if approved, has the potential to be the first once-weekly basal insulin ...

Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.

Compared with once-daily comparators, once-weekly icodec was associated with similar safety and efficacy outcomes regardless of race, ethnicity, or age. The hypoglycemic profile and efficacy of ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found. In QWINT-1, there was a similar ...

In a phase 3a trial involving adults with type 2 diabetes who had not previously received insulin, glycemic control was better with once-weekly insulin icodec than with once-daily insulin glargine ...